Abstract:The conversion yield is enhanced through the discovery of an intramolecular π‐π interaction between the target molecule and a photoremovable protective group, which is achieved by chemical modification of the prodrug. A triplet–triplet annihilation‐mediated photocleavage approach is developed to prevent tumor vascular growth for synergistic tumor treatment in conjunction with a red‐light photosensitizer. Highly spatiotemporal‐resolved photomodulation demonstrates promise for investigating key biological events in vivo and in vitro, such as cell signaling pathways, neuromodulation, and tumor treatment without side effects. However, enhancing the performance of photomodulation tools remains challenging due to the limitations of the physicochemical properties of the photoactive molecules. Here, a compact, stable intramolecular π‐π stacking conformation forming between the target molecule (naproxen) and the perylene‐based photoremovable protecting group is discovered to confine the motion of the photolabile bond and then enhance the photocleavage quantum yield. In conjunction with a red‐absorbing photosensitizer, the photocleavage wavelength is extended to the red region via triplet–triplet annihilation. In particular, the triplet lifetime of the prodrug can be extended via the linked steric hindrance to improve the conversion yield via TTA. Using the new photomodulation tool, it is precisely photoreleased cyclooxygenase‐2 inhibitors for tumor vascular growth suppression in vivo. In combination with cisplatin, over 90% efficient inhibition of malignant breast tumors is observed via the synergistic tumor treatment strategy. These findings provide a new concept for the rational design of efficient photocleavage and have implications for photomodulating cell signaling pathways in tumor therapy, as well as laying a solid foundation for the development of phototherapeutic approaches.

Photoredox-catalyzed reaction as a powerful tool for rapid natural product Gem -dimethylation modification: discovery of potent anti-cancer agents with improved druggability

Antitumor Agents 268. Design, Synthesis, and Mechanistic Studies of New 9-Substituted Phenanthrene-Based Tylophorine Analogues As Potent Cytotoxic Agents.

Design, synthesis and in vitro evaluation of tylophorine derivatives as possible anti-tumor agents.

Structure Modification and Biological Evaluation of Indole-Chalcone Derivatives As Anti-Tumor Agents Through Dual Targeting Tubulin and TrxR.

Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms.

Compact Molecular Conformation of Prodrugs Enhances Photocleaving Performance for Tumor Vascular Growth Inhibition

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Synthesis and Bioactivity of Novel Dihydrofolate Reductase Inhibitor

Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma.

Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity.

Oxidized analogs of Di(1 H -indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity.

Dual Diomarkers Triggered Prodrugs for Precise Treatment of Melanoma: Design, Synthesis and Activities

The AIE‐Active Dual‐Cationic Molecular Engineering: Synergistic Effect of Dark Toxicity and Phototoxicity for Anticancer Therapy

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Synthesis of Naphthazarin Derivatives and Identification of Novel Thioredoxin Reductase Inhibitor As Potential Anticancer Agent

Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents.

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Synthesis and biological evaluation of novel demethylzeylasteral derivatives as potential anticancer agents

Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy

TRC4, an Improved Triptolide Derivative, Specifically Targets to Truncated Form of Retinoid X Receptor-Alpha in Cancer Cells.

Disruption of Ferroptosis Inhibition and Immune Evasion with Tumor‐Activatable Prodrug for Boosted Photodynamic/Chemotherapy Eradication of Drug‐Resistant Tumors